BofA raises target for Biogen stock to USD 244.00

Published on 10/24/2026 at 21:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Growth products reached USD 1.06 billion in Q2 2026, up 24.00 percent year over year. Biogen stock costs EUR 223.78 on October 24, 2026, down 0.54 percent versus the Tradegate close.

Analyst target and results date

BofA Securities raised its Biogen target from USD 219.00 to USD 244.00 on October 22, 2026.
Biogen's growth portfolio generated USD 1.06 billion in the second quarter of 2026, up 24.00 percent year over year.
Biogen stock costs EUR 223.78 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, down 0.54 percent versus the Tradegate close of October 23, 2026.
Biogen is scheduled to report third-quarter results on October 28, 2026.

NASDAQ-Handelsfloor mit grünem BIOTECH INDEX-Anzeigetafel und Händlern an Bildschirmen — Biogen Inc. Biotech-Aktie an der NASDAQ mit steigendem Kursindex im Handelsaal ISIN US09062X1037, Illustration mit AI erstellt.

Biogen Inc. (US09062X1037) drew a fresh valuation signal on October 22, 2026, when BofA Securities raised its price target from USD 219.00 to USD 244.00 while keeping a Neutral rating, as Investing.com reported. The move came ahead of Biogen's third-quarter results. Biogen stock was trading at EUR 223.78 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, down 0.54 percent versus the Tradegate close of October 23, 2026 at EUR 225.00.

Growth products change the mix

The most important operating shift is inside Biogen's second-quarter portfolio. According to Zacks Investment Research on September 28, 2026, growth products generated USD 1.06 billion, up 24.00 percent year over year and 25.00 percent from the prior quarter. That exceeded the USD 767.00 million from Biogen's legacy multiple sclerosis portfolio.

Revenue from Skyclarys increased 29.00 percent year over year to USD 168.00 million in the second quarter, while Zurzuvae revenue rose 53.00 percent to USD 71.00 million. Vumerity revenue fell 7.40 percent to USD 196.50 million, showing why the product mix matters for the upcoming report.

What does the target imply?

BofA's USD 244.00 target sits above the latest US market quote but below the USD 250.00 target set by TD Cowen on October 21, 2026. TD Cowen maintained a Buy rating and changed its non-GAAP third-quarter earnings-per-share estimate to USD 1.99 from USD 1.90, according to Investing.com.

Biogen's second-quarter 2026 revenue was USD 2.736 billion, compared with USD 2.4778 billion in the first quarter, while diluted earnings per share were USD 0.66 versus USD 2.15. The next scheduled date is October 28, 2026, when Biogen is due to report third-quarter results.

Stock position and valuation

The latest US quote was USD 250.69 at the Nasdaq on October 23, 2026 at 4:00 p.m. ET. Biogen's 52-week range was USD 138.00 to USD 254.41, and its market capitalization was USD 37.0 billion at that market snapshot. Its reported price-to-earnings ratio was 44.37.

Biogen's operating picture therefore combines a newer portfolio that is growing faster than legacy multiple sclerosis products with a valuation debate centered on pipeline execution and the October 28 report. The price target changes provide a measurable test for that debate.

Biogen stock was trading at EUR 223.78 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, down 0.54 percent versus the Tradegate close of October 23, 2026 at EUR 225.00. The further course of trading is shown by the continuously updated real-time quote of Biogen stock.